National Immunization Strategy. Advocacy to seek continued funding in vaccines.
Legislative Proposal, Bill or Resolution, Policies or Program, Regulation
Consider amendments to the Food and Drugs Act, or the Export and Imports Permits Act (Export Control List) or any other legislative and regulatory means in order to protect the Canadian supply of drugs in light of potential importation legislation in the United States.
Legislative Proposal, Bill or Resolution, Regulation
Patent Act and the Intellectual property provisions as it relates to the adoption, ratification and eventual implementation of the Bill C-100, An Act to implement the Agreement between Canada, the United States of America and the United Mexican States Intellectual property protection provisions.
Policies or Program
Federal Public Drug Plans, with respect to the reimbursement of therapeutic products for Federal plan beneficiaries
Health Canada’s policies, program and guidelines related to the management, prevention, mitigation and notification of drug shortages
Patented Medicine Prices Review Board (PMPRB)consultation on the proposed modernization of the Compendium of Policies, Guidelines and Procedures
The Department of Innovation, Science and Economic Development and its Innovation Agenda for the life sciences sector: policy or program initiatives to support life science Research and Development conducted in Canada
Policies or Program, Regulation
Regulations, policies and programs related to the reimbursement recommendations decision-making process and framework done by the Canadian Agency for Drugs and Technologies in Health (CADTH)/Common Drug Review as well as the review times and processes conducted by Health Canada for the purpuse of obtaining a notice of compliance.
Subsequent Entry Biologics (SEBs) and Orphan Drugs framework: seeking an approval framework supported and protected by Regulations in harmonization with other developed countries
Regulation
Proposed modernization of the Patented Medicines Prices Review Board (PMPRB) Regulations in the consultation document “Protecting Canadians from Excessive Drug Prices”